E. Langevin

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

P. Pitisuttithum, K. Rusmil, D. Vliet, 2014, The Lancet.

Efficacy of a tetravalent dengue vaccine in children in Latin America.

G. Carrasquilla, R. Dietze, M. Saville, 2015, The New England journal of medicine.

Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials

Lindsay N. Carpp, B. Guy, A. Fiore-Gartland, 2018, Proceedings of the National Academy of Sciences.

Epidemiology of invasive meningococcal disease and sequelae in the United Kingdom during the period 2008 to 2017 – a secondary database analysis

E. Langevin, S. Guedes, H. Bricout, 2022, BMC Public Health.

Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.

P. Gilbert, C. Diazgranados, Z. Moodie, 2020, Vaccine.

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

T. Westling, P. Gilbert, S. Gurunathan, 2018, The New England journal of medicine.

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy

Y. Girerd-Chambaz, C. Simmons, N. Jackson, 2017, eLife.

Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.

C. Diazgranados, E. Langevin, C. Frago, 2020, Vaccine.

Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand

E. Langevin, C. Frago, T. Wartel, 2019, Asian Pacific Journal of Tropical Medicine.

Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.

N. H. Tran, S. Hadinegoro, T. Chotpitayasunondh, 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease

M. Halloran, P. Gilbert, P. Pitisuttithum, 2018, PloS one.

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals

C. Diazgranados, S. Sridhar, E. Langevin, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America

C. Diazgranados, E. Langevin, G. Dayan, 2020, The American journal of tropical medicine and hygiene.

Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States

E. Langevin, P. Faivre, R. Noharet-Koenig, 2023, MDM policy & practice.